Related Experiment Videos
Endostatin: a promising drug for antiangiogenic therapy
L Cirri1, S Donnini, L Morbidelli
1Department of Pharmacology, University of Firenze, Italy.
Abstract:
Angiogenesis, the formation of new blood vessels from existing capillaries, is critical for tumors to grow beyond a few in size. Tumor cells produce one or more angiogenic factors including fibroblast growth factor and vascular endothelial growth factor. Surprisingly, antiangiogenic factors or angiogenesis inhibitors have been isolated from tumors. Some angiogenesis inhibitors, such as angiostatin, are associated with tumors while others, such as platelet-factor 4 and interferon-alpha are not. Endostatin, a C-terminal product of collagen XVIII, is a specific inhibitor of endothelial cell proliferation, migration and angiogenesis. The mechanism by which endostatin inhibits endothelial cell proliferation and migration is unknown. Endostatin was originally expressed in a prokaryotic system and, late, in a yeast system, thanks to which it is possible to obtain a sufficient quantity of the protein in a soluble and refolded form to be used in preclinical and clinical trials.
Insights
Tumor growth relies on angiogenesis, the creation of new blood vessels. Endostatin, an angiogenesis inhibitor derived from collagen XVIII, shows promise for cancer therapy by blocking tumor blood vessel formation.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Angiogenesis is essential for tumor growth, driven by factors like fibroblast growth factor and vascular endothelial growth factor.
- Tumors can produce both pro-angiogenic and anti-angiogenic factors.
- Endostatin, derived from collagen XVIII, specifically inhibits endothelial cell proliferation, migration, and angiogenesis.
Purpose of the Study:
- To investigate the role and production of endostatin as an angiogenesis inhibitor.
- To explore the potential of endostatin in cancer therapy.
Main Methods:
- Expression of endostatin in prokaryotic and yeast systems.
- Obtaining soluble and refolded endostatin protein for preclinical and clinical use.
Main Results:
- Endostatin was successfully produced in sufficient quantities in soluble and refolded forms.
- Endostatin demonstrated specific inhibition of endothelial cell proliferation, migration, and angiogenesis.
Conclusions:
- Endostatin is a potent angiogenesis inhibitor with potential therapeutic applications in cancer.
- The production of endostatin via recombinant systems facilitates its use in preclinical and clinical studies.